1. Home
  2. News
  3. Dimerix Limited
  4. DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24
More Dimerix Limited news
Dimerix LimitedASX: DXB

DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24

Jul 23, 2023 at 10:53 PM EDT · Issued by Dimerix Limited

Filed with ASX · Jul 23, 2023 at 10:53 PM EDT · 4 pages · English

On 6ix: 6ix.com/news/dmx-200-fsgs-ph3-kidney-trial-part-1-outcome-set-for-q1-cy24

Dimerix Limited on 6ix

In the deck

  • Dimerix — Bioshares Biotech Summit 202319 slidesJul 24, 2023

Story so far

  • Successful Completion of DSMB Review of Phase 3 FSGS TrialFeb 9, 2023
  • DMX-200 FSGS Phase 3 Trial Part 1 Recruitment AchievedDec 15, 2022
  • CLARITY 2.0 COVID-19 Study OutcomeDec 13, 2022

Earlier from Dimerix

  • Approval received for Paediatric Investigation Plan from EMAJul 4, 2023
  • Dimerix confirms Phase 3 study design appropriate for ChinaJul 2, 2023
  • ProspectusJun 26, 2023
  • Dimerix Announces Update on Successful Capital RaiseJun 5, 2023
  • Rights Issue ProspectusMay 4, 2023

Later from Dimerix

  • Successful Completion of 2nd DSMB Review of FSGS TrialAug 7, 2023
  • Dimerix Receives $8.9M R&D Tax Incentive RebateSep 12, 2023
  • Regulatory Approval received in Malaysia for ACTION3 StudySep 21, 2023
  • FDA Approves Qytovra Brand NameSep 24, 2023
  • Dimerix Announces License Agreement for EU, Canada, ANZOct 4, 2023
All Dimerix news releases↗

Follow Dimerix into a list and get an email when it puts out news.

Follow Dimerix
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer